Log In
BCIQ
Print this Print this
 

Ace-ER, NPC-09, UX-001

Also known as: formerly SA-ER, UX001

  Manage Alerts
Collapse Summary General Information
Company Nobelpharma Co. Ltd.
DescriptionExtended-release oral formulation of aceneuramic acid
Molecular Target
Mechanism of ActionSubstrate replacement therapy
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMuscular atrophy
Indication DetailsTreat GNE myopathy (GNEM)/hereditary inclusion body myopathy (HIBM)
Regulatory Designation U.S. - Orphan Drug (Treat GNE myopathy (GNEM)/hereditary inclusion body myopathy (HIBM));
EU - Orphan Drug (Treat GNE myopathy (GNEM)/hereditary inclusion body myopathy (HIBM))
PartnerUltragenyx Pharmaceutical Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today